X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON LTD ALKEM LABORATORIES/
BIOCON LTD
 
P/E (TTM) x - 41.2 - View Chart
P/BV x 6.3 7.2 87.6% View Chart
Dividend Yield % 0.7 0.2 427.5%  

Financials

 ALKEM LABORATORIES   BIOCON LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON LTD
Mar-18
ALKEM LABORATORIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,188 133.8%   
Low Rs1,232305 403.9%   
Sales per share (Unadj.) Rs417.568.7 607.4%  
Earnings per share (Unadj.) Rs56.37.6 745.5%  
Cash flow per share (Unadj.) Rs64.714.0 463.2%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.1 672.1%  
Book value per share (Unadj.) Rs292.986.3 339.3%  
Shares outstanding (eoy) m119.57600.00 19.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.410.9 31.1%   
Avg P/E ratio x25.198.9 25.3%  
P/CF ratio (eoy) x21.853.4 40.8%  
Price / Book Value ratio x4.88.6 55.7%  
Dividend payout %22.613.2 170.4%   
Avg Mkt Cap Rs m168,653447,900 37.7%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m9,1719,311 98.5%   
Avg. sales/employee Rs ThNM6,705.8-  
Avg. wages/employee Rs ThNM1,514.2-  
Avg. net profit/employee Rs ThNM736.9-  
INCOME DATA
Net Sales Rs m49,91541,234 121.1%  
Other income Rs m1,6452,062 79.8%   
Total revenues Rs m51,56143,296 119.1%   
Gross profit Rs m8,4828,291 102.3%  
Depreciation Rs m1,0063,851 26.1%   
Interest Rs m671615 109.0%   
Profit before tax Rs m8,4515,887 143.6%   
Minority Interest Rs m-114213 -53.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,569 102.4%   
Profit after tax Rs m6,7314,531 148.6%  
Gross profit margin %17.020.1 84.5%  
Effective tax rate %19.026.7 71.3%   
Net profit margin %13.511.0 122.7%  
BALANCE SHEET DATA
Current assets Rs m27,06241,486 65.2%   
Current liabilities Rs m15,32421,413 71.6%   
Net working cap to sales %23.548.7 48.3%  
Current ratio x1.81.9 91.2%  
Inventory Days Days6764 104.0%  
Debtors Days Days4194 43.8%  
Net fixed assets Rs m12,61050,661 24.9%   
Share capital Rs m2393,000 8.0%   
"Free" reserves Rs m34,49048,808 70.7%   
Net worth Rs m35,02751,808 67.6%   
Long term debt Rs m1,21217,898 6.8%   
Total assets Rs m54,38799,897 54.4%  
Interest coverage x13.610.6 128.7%   
Debt to equity ratio x00.3 10.0%  
Sales to assets ratio x0.90.4 222.4%   
Return on assets %13.65.2 264.2%  
Return on equity %19.28.7 219.7%  
Return on capital %24.99.6 258.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56312,058 54.4%   
Fx outflow Rs m3,0127,348 41.0%   
Net fx Rs m3,5524,710 75.4%   
CASH FLOW
From Operations Rs m7,2596,621 109.6%  
From Investments Rs m1,864-6,840 -27.3%  
From Financial Activity Rs m-9,273-2,397 386.8%  
Net Cashflow Rs m-150-2,612 5.7%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS